{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T07:16:51Z","timestamp":1715584611378},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1007\/bf02938377","type":"journal-article","created":{"date-parts":[[2008,8,15]],"date-time":"2008-08-15T07:34:25Z","timestamp":1218785665000},"page":"289-297","source":"Crossref","is-referenced-by-count":3,"title":["New anticoagulant options for ST-elevation myocardial infarction and unstable angina pectoris\/non-ST-elevation myocardial infarction"],"prefix":"10.1007","volume":"9","author":[{"given":"Eric R.","family":"Bates","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02938377_CR1","first-page":"e82","volume":"110","author":"EM Antman","year":"2004","unstructured":"Of major importance Antman EM, Anbe DT, Armstrong PW, et al.:ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines (Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction).Circulation 2004,110:e82-e292. ACC\/AHA guidelines for STEMI.","journal-title":"Circulation"},{"key":"BF02938377_CR2","unstructured":"Antman EM, Hand M, Armstrong PW, et al.:June 2007 focused update of the ACC\/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. A report of the American College of Cardiology\/American Heart Association task force on practice guidelines.Circulation 2007, in press."},{"key":"BF02938377_CR3","first-page":"28","volume":"24","author":"F Werf Van de","year":"2003","unstructured":"Van de Werf F, Ardissino D, Betriu A, et al.:Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European Society of Cardiology.Eur Heart J 2003,24:28\u201366.","journal-title":"Eur Heart J"},{"key":"BF02938377_CR4","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/01.CIR.0000030314.11999.6A","volume":"106","author":"E Braunwald","year":"2002","unstructured":"Braunwald E, Antman EM, Beasley JW, et al.:ACC\/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article. A report of the American College of Cardiology\/American Heart Association task force on practice guidelines (Committee on the management of patients with unstable angina).Circulation 2002,106:1893\u20131900.","journal-title":"Circulation"},{"key":"BF02938377_CR5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1053\/euhj.2002.3385","volume":"23","author":"ME Bertrand","year":"2002","unstructured":"Bertrand ME, Simoons ML, Fox KA, et al.:Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.Eur Heart J 2002,23:1809\u20131840.","journal-title":"Eur Heart J"},{"key":"BF02938377_CR6","first-page":"2067","volume-title":"Braunwald\u2019s Heart Disease","author":"BA Konkle","year":"2005","unstructured":"Konkle BA, Schafer AI:Hemostasis, thrombosis, fibrinolysis, and cardiovascular disease. InBraunwald\u2019s Heart Disease, vol 2, edn 7. Edited by Braunwald E, Zipes DP, Libby P, Bonow RO. Philadelphia: WB Saunders; 2005:2067\u20132092.","edition":"edn 7"},{"key":"BF02938377_CR7","doi-asserted-by":"crossref","unstructured":"Bates ER:Bivalirudin: an anticoagulant option for percutaneous coronary intervention Expert Rev Cardiovasc Ther 2004:153\u2013162.","DOI":"10.1586\/14779072.2.2.153"},{"key":"BF02938377_CR8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V100.1.148","volume":"100","author":"KE Brummel","year":"2002","unstructured":"Brummel KE, Paradis SG, Butenas S, Mann KG:Thrombin functions during tissue factor-induced blood coagulation.Blood 2002,100:148\u2013152.","journal-title":"Blood"},{"key":"BF02938377_CR9","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1055\/s-0037-1615947","volume":"85","author":"M Hoffman","year":"2001","unstructured":"Hoffman M, Monroe DM:A cell-based model of hemostasis.Thromb Haemost 2001,85, 958\u2013965.","journal-title":"Thromb Haemost"},{"key":"BF02938377_CR10","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1161\/01.ATV.0000031340.68494.34","volume":"22","author":"DM Monroe","year":"2002","unstructured":"Monroe DM, Hoffman M, Roberts HR:Platelets and thrombin generation.Arterioscler Thromb Vasc Biol 2002,22:1381\u20131389.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BF02938377_CR11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/35025229","volume":"407","author":"SR Coughlin","year":"2000","unstructured":"Coughlin SR:Thrombin signaling and protease-activated receptors.Nature 2000,407:258\u2013264.","journal-title":"Nature"},{"key":"BF02938377_CR12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","volume":"329","author":"The GUSTO Investigators","year":"1993","unstructured":"The GUSTO Investigators:An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.N Engl J Med 1993,329:673\u2013682.","journal-title":"N Engl J Med"},{"key":"BF02938377_CR13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJM199703203361207","volume":"336","author":"R Collins","year":"1997","unstructured":"Collins R, Peto R, Baigent C, Sleight P:Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction.N Engl J Med 1997,336:847\u2013860.","journal-title":"N Engl J Med"},{"key":"BF02938377_CR14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.289.3.331","volume":"289","author":"GC Wong","year":"2003","unstructured":"Wong GC, Giugliano RP, Antman EM:Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention.JAMA 2003,289:331\u2013342.","journal-title":"JAMA"},{"key":"BF02938377_CR15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(01)05775-0","volume":"358","author":"ASSENT-3 Investigators","year":"2001","unstructured":"ASSENT-3 Investigators:Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.Lancet 2001,358:605\u2013613.","journal-title":"Lancet"},{"key":"BF02938377_CR16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.0000081659.72985.A8","volume":"108","author":"L Wallentin","year":"2003","unstructured":"Wallentin L, Goldstein P, Armstrong PW, et al.:Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 plus randomized trial in acute myocardial infarction.Circulation 2003,108:135\u2013142.","journal-title":"Circulation"},{"key":"BF02938377_CR17","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","volume":"354","author":"EM Antman","year":"2006","unstructured":"Of importance Antman EM, Morrow DA, McCabe CH, et al.:Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.N Engl J Med 2006,354:1477\u20131488. This trial established enoxaparin as an anticoagulant option in patients with STEMI treated with fibrinolytic therapy.","journal-title":"N Engl J Med"},{"key":"BF02938377_CR18","doi-asserted-by":"crossref","unstructured":"Gibson CM, Murphy SA, Montalescot G, et al.:Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin following fibrinolytic therapy for ST-elevation myocardial infarction in the EXTRACT-TIMI 25 trial.J Am Coll Cardiol 2007, in press.","DOI":"10.1016\/j.jacc.2007.01.093"},{"key":"BF02938377_CR19","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","volume":"295","author":"S Yusuf","year":"2006","unstructured":"Of importance Yusuf S, Mehta SR, Chrolavicius S, et al.:Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. The OASIS-6 randomized trial.JAMA 2006,295:1519\u20131530. This trial established fondaparinux as an anticoagulant option in patients with STEMI not undergoing early PCI.","journal-title":"JAMA"},{"key":"BF02938377_CR20","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/01.CIR.96.7.2155","volume":"96","author":"HD White","year":"1997","unstructured":"White HD, Aylward PE, Frey MJ, et al.:Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion\/Occlusion (HERO) trial investigators.Circulation 1997,96:2155\u20132161.","journal-title":"Circulation"},{"key":"BF02938377_CR21","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(01)06961-6","volume":"358","author":"H White","year":"2001","unstructured":"White H:Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial.Lancet 2001,358:1855\u20131863.","journal-title":"Lancet"},{"key":"BF02938377_CR22","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","volume":"355","author":"JW Eikelboom","year":"2000","unstructured":"Eikelboom JW, Anand SS, Malmberg K, et al.:Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.Lancet 2000,355:1936\u20131942.","journal-title":"Lancet"},{"key":"BF02938377_CR23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","volume":"337","author":"M Cohen","year":"1997","unstructured":"Cohen M, Demers C, Gurfinkel EP, et al.:A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease.N Engl J Med 1997,337:447\u2013452.","journal-title":"N Engl J Med"},{"key":"BF02938377_CR24","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","volume":"100","author":"EA Antman","year":"1999","unstructured":"Antman EA, McCabe CH, Gurfinkel EP, et al.:Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction: results of the TIMI 11B trial.Circulation 1999,100:1593\u20131601.","journal-title":"Circulation"},{"key":"BF02938377_CR25","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.100.15.1602","volume":"100","author":"EM Antman","year":"1999","unstructured":"Antman EM, Cohen M, Radley D, et al.:Assessment of the treatment effect of enoxaparin for unstable angina\/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.Circulation 1999,100:1602\u20131608.","journal-title":"Circulation"},{"key":"BF02938377_CR26","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1067\/mhj.2002.126115","volume":"144","author":"M Cohen","year":"2002","unstructured":"Cohen M, Theroux P, Borzak S, et al.:Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study.Am Heart J 2002,144:470\u2013477.","journal-title":"Am Heart J"},{"key":"BF02938377_CR27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/01.CIR.0000050144.67910.13","volume":"107","author":"SG Goodman","year":"2003","unstructured":"Goodman SG, Fitchett D, Armstrong PW, et al.:Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb\/IIIa inhibitor eptifibatide.Circulation 2003,107:238\u2013244.","journal-title":"Circulation"},{"key":"BF02938377_CR28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jama.292.1.55","volume":"292","author":"MA Blazing","year":"2004","unstructured":"Blazing MA, de Lemos JA, White HD, et al.:Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.JAMA 2004,292:55\u201364.","journal-title":"JAMA"},{"key":"BF02938377_CR29","first-page":"45","volume":"292","author":"The SYNERGY Trial Investigators","year":"2004","unstructured":"Of importance The SYNERGY Trial Investigators:Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.JAMA 2004,292:45\u201354. Most recent trial of enoxaparin in NSTE-ACS.","journal-title":"JAMA"},{"key":"BF02938377_CR30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jama.292.1.89","volume":"292","author":"JL Petersen","year":"2004","unstructured":"Petersen JL, Mahaffey KW, Hasselblad V, et al.:Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes. A systemic overview.JAMA 2004,292:89\u201396.","journal-title":"JAMA"},{"key":"BF02938377_CR31","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","volume":"354","author":"S Yusuf","year":"2006","unstructured":"Of importance Yusuf S, Mehta SR, Chrolavicius S, et al.: for the OASIS-5 Investigators:Comparison of fondaparinux and enoxaparin in acute coronary syndromes.N Engl J Med 2006,354:1464\u20131476. This trial established fondaparinux as an anticoagulant option in patients with NSTE-ACS.","journal-title":"N Engl J Med"},{"key":"BF02938377_CR32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1067\/mhj.2002.120405","volume":"143","author":"EM Antman","year":"2002","unstructured":"Antman EM, McCabe CH, Braunwald E:Bivalirudin as a replacement for unfractionated heparin in unstable angina\/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial.Am Heart J 2002,143:229\u2013234.","journal-title":"Am Heart J"},{"key":"BF02938377_CR33","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","volume":"289","author":"AM Lincoff","year":"2003","unstructured":"Lincoff AM, Bittl JA, Harrington RA, et al.: for the REPLACE-2 Investigators:Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial.JAMA 2003:289:853\u2013863.","journal-title":"JAMA"},{"key":"BF02938377_CR34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ahj.2005.09.007","volume":"152","author":"V Rajagopal","year":"2006","unstructured":"Rajagopal V, Lincoff AM, Cohen DJ, et al.:Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.Am Heart J 2006,152:149\u2013154.","journal-title":"Am Heart J"},{"key":"BF02938377_CR35","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.jacc.2005.12.077","volume":"47","author":"CM Gibson","year":"2006","unstructured":"Gibson CM, Morrow DA, Murphy SA, et al.:A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI 30 trial.J Am Coll Cardiol 2006,47:2364\u20132373.","journal-title":"J Am Coll Cardiol"},{"key":"BF02938377_CR36","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","volume":"355","author":"GW Stone","year":"2006","unstructured":"Of importance Stone GW, McLaurin BT, Cox DA, et al.: for the ACUITY Investigators:Bivalirudin for patients with acute coronary syndromes.N Engl J Med 2006,355:2203\u20132216. This trial established bivalirudin as an anticoagulant option in patients with NSTE-ACS undergoing early PCI.","journal-title":"N Engl J Med"},{"key":"BF02938377_CR37","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(07)60450-4","volume":"369","author":"GW Stone","year":"2007","unstructured":"Stone GW, White HD, Ohman EM, et al.:Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.Lancet 2007,369:907\u2013919.","journal-title":"Lancet"},{"key":"BF02938377_CR38","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/01.CIR.93.5.870","volume":"93","author":"CB Granger","year":"1996","unstructured":"Granger CB, Hirsch J, Califf RM, et al.:Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-1 trial.Circulation 1996,93:870\u2013878.","journal-title":"Circulation"},{"key":"BF02938377_CR39","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.amjcard.2005.06.056","volume":"96","author":"SV Rao","year":"2005","unstructured":"Rao SV, O\u2019Grady K, Pieper KS, et al.:Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes.Am J Cardiol 2005,96:1200\u20131206.","journal-title":"Am J Cardiol"},{"key":"BF02938377_CR40","first-page":"3108","volume":"295","author":"KP Alexander","year":"2006","unstructured":"Alexander KP, Chen AY, Roe MT, et al.:Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-elevation acute coronary syndromes.JAMA 2006,295:3108\u20133116.","journal-title":"JAMA"},{"key":"BF02938377_CR41","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.292.13.1555","volume":"292","author":"SV Rao","year":"2004","unstructured":"Rao SV, Jollis JG, Harrington RA, et al.:Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes.JAMA 2004,292:1555\u20131562.","journal-title":"JAMA"},{"key":"BF02938377_CR42","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1538-7836.2005.01374.x","volume":"3","author":"JI Weitz","year":"2005","unstructured":"Weitz JI, Bates SM:New anticoagulants.J Thromb Haemost 2005,3:1843\u20131853.","journal-title":"J Thromb Haemost"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02938377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02938377\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02938377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T22:58:38Z","timestamp":1558565918000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02938377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["BF02938377"],"URL":"https:\/\/doi.org\/10.1007\/bf02938377","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}